Table 4.
Characteristics of patients who received anti-EGFR therapy
| Characteristics | All WTa | Any MTb | Pvalue | |
|---|---|---|---|---|
| (n= 56, %) | (n= 10, %) | |||
| Age | Median (range) | 64 (34–79) | 64 (51–74) | 0.629* |
| ECOG PS | 0 | 38 (67.9) | 3 (30.0) | 0.034** |
| 1–2 | 18 (32.1) | 7 (70.0) | ||
| Primary lesion | Colon | 35 (62.5) | 5 (50.0) | 0.498** |
| Rectum | 21 (37.5) | 5 (50.0) | ||
| Histology | Well, mod | 53 (94.6) | 8 (80.0) | 0.162** |
| Por, muc | 3 (5.4) | 2 (20.0) | ||
| Number of metastasis | 1 | 14 (25.0) | 4 (40.0) | 0.442** |
| >2 | 42 (75.0) | 6 (60.0) | ||
| Treatment line of anti-EGFR mab | 2nd line | 27 (48.2) | 3 (30.0) | 0.327** |
| 3rd line | 29 (51.8) | 7 (70.0) | ||
| Treatment | Combination therapy | 44 (78.6) | 3 (30.0) | 0.004** |
| Monotherapy | 12 (21.4) | 7 (70.0) | ||
| Gene mutation | KRAS codon 61, 146 | - | 3 | |
| NRAS codon12, 13, 61 | - | 2 | ||
| PIK3CA exon 9, 20 | - | 3 | ||
| BRAF codon 600 | - | 3 | ||
*Mann–Whitney U test; **χ2 or Fisher exact test. aWild type KRAS codons 61, 146, NRAS, BRAF and PIK3CA; bany mutations in KRAS codons 61 or 146, NRAS, BRAF or PIK3CA. mab: monoclonal antibody.